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Background: Osteoarthritis (OA) is a major health problem in the increasingly elderly population. Therefore, it is
crucial to prevent and treat OA at an early stage. The present study investigated whether pamidronate disodium
(PAM), a bone-loss inhibitor, can significantly prevent or reverse the progression of early anterior cruciate ligament
transection (ACLT)-induced OA. Whether therapeutic intervention is associated with regulation of the expression of
osteoprotegerin (OPG), receptor activator of nuclear factor-κB ligand (RANKL), metalloproteinase-9 (MMP-9) or
Toll-like receptor-4 (TLR-4) in cartilage and/or subchondral bone was also investigated.
Methods: 60 New Zealand rabbits were randomized into four groups: Sham-operated (n = 20); ACLT (n = 20);
short-term treatment with PAM (PAM-S, n = 10) and long-term treatment with PAM (PAM-L, n = 10). For cartilage
and subchondral bone testing, rabbits from Sham and ACLT groups were harvested at 2, 4, 6, and 14 weeks. Rabbits
were given PAM from the 4th week after ACLT operation in PAM-S and PAM-L group, and were harvested at 6 and
14 weeks, respectively. Trabecular characteristics and cartilage changes were detected using Micro-CT, safranin O
and rapid green staining, respectively. Immunohistochemical staining for OPG and RANKL were also performed.
OPG, RANKL, MMP-9 and TLR-4 expression was evaluated by western blot analysis.
Results: Micro-CT and histology analyses indicated that PAM treatment for 2 or 10 weeks could completely prevent
or reverse osteoarthritic subchondral bone loss and cartilage surface erosion. Immunohistochemistry and western
blot analysis indicated that expression of OPG and RANKL increased, although RANKL expression increased more
significantly than that of OPG. Therefore the ratio of OPG to RANKL was lower in the ACLT group. However, the
ratio of OPG to RANKL in the PAM group was significantly higher than that in the ACLT group. Additionally,
expression of MMP-9 and TLR-4 were upregulated in the ACLT group and downregulated in the PAM treated
groups.
Conclusions: PAM can significantly inhibit and even reverse early osteoarthritic subchondral bone loss, thus
alleviating the process of cartilaginous degeneration. The mechanisms involved may be associated with the
upregulation of OPG expression, and downregulation of RANKL, MMP-9 and TLR-4 expression.
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Osteoarthritis (OA) is a degenerative joint disease charac-
terized by progressive cartilaginous degeneration, osteo-
phyte formation, subchondral bone changes and synovial
inflammation [1,2]. Although cartilage lesions are the main
feature of OA, increasing evidence indicates that it is also a
bone disease [3,4]. Radin et al. [5] were the first to propose
that subchondral bone may cause cartilaginous degene-
ration. Thereafter, multiple reports have suggested that
changes in subchondral bone may alter the load distribu-
tion, and so becoming an important inducing or accelera-
ting cause for cartilaginous injury in OA [3,6,7]. Recent
animal experiments have shown that early-stage OA is
accompanied by a reduction in bone volume, indicating
that the initial subchondral bone resorption may be a
crucial factor for OA onset and progression [8,9]. How-
ever, Bobinac et al. [10] have posited that changes in sub-
chondral bone could exist during or after cartilaginous
degeneration. Therefore, determining the exact effects of
subchondral bone on the occurrence and development of
OA, particularly during the early stage, is of crucial im-
portance in seeking new diagnostic markers and thera-
peutic targets for OA [2,4].
Subchondral bone mass is maintained through a balance
between formation and resorption during the develop-
ment of OA. In the bone resorption process, regardless of
the pathology, the osteoclast is the exclusive resorptive cell
[11]. A signaling molecule composed of osteoprotegerin/
receptor activator of nuclear factor-κ B/RANK ligand
(OPG/RANK/RANKL) has been described as critical in
controlling osteoclast biology. RANKL, synthesized by
osteoblasts, binds to RANK on the osteoclast precursor
membrane and is an essential factor for osteoclast differ-
entiation and bone resorption [12,13]. OPG, which is also
produced by osteoblasts, acts as a soluble decoy receptor
for RANKL. Also, by interacting with RANKL, OPG pre-
vents RANK activation and subsequent osteoclastogene-
sis, resulting in the inhibition of bone resorption [14]. It
was recently reported that when OPG was transferred
onto cartilage explants, it resulted in a marked decrease in
aggrecan cleavage and cartilage proteoglycan release, dem-
onstrating the role of OPG in the regulation of cartilage
catabolism [1]. Thus, although the roles of these cytokines
secreted by the chondrocytes in the onset and progression
of subchondral bone changes in OA are hypothesized,
they remain to be fully investigated.
A recent study has shown that cartilage damage in OA is
caused by disruption of the balance between catabolic and
anabolic function of chondrocytes [15]. Catabolic activities
of OA chondrocytes are related to the elevated release of
cartilage degrading enzymes, such as matrix metallopro-
teinases (MMPs) [16], while in anabolic activities, Toll-like
receptor 4 (TLR4) has been shown to play a crucial role in
inflammatory signaling in human chondrocytes [15].As the goal of modern medicine shifts towards disease
prevention, subchondral bone may represent an attractive
candidate as a therapeutic target in early OA. Therefore,
bone-loss inhibitors, such as pamidronate disodium (PAM)
and other bisphosphonates, might be potential therapeutic
drugs for OA [17]. Kadri et al. have proposed that the level
of bone resorption influences cartilage metabolism and the
inhibition of bone resorption might prevent the progres-
sion of OA [18]. In studies of ovariectomized mice, PAM
was efficacious in treating OA with osteoporosis [1]. Even
though alendronate, also a member of the bisphosphonate
family, has been shown to prevent subchondral bone le-
sions and to reduce knee pain in clinical trials, it is unable
to stop the progression of OA [19]. Additionally, a recent
study Zoledronic acid, in a high-dose regimen, proved to
be chondroprotective in a well-established animal model of
OA [20]. At present, in the reported preclinical studies,
most of the drug treatment programs have been initiated
several days before or on the day of OA model establish-
ment [1,3,18,21,22]. However, the perfect timing of clinical
treatment for OA is unpredictable and impractical; that is,
it would be impossible to intervene with drug treatments
before OA onset. Therefore, drug intervention after the
formation of early OA is more clinically meaningful. Stu-
dies in this area are rare, and whether PAM is able to pre-
vent or reverse the progression of early-stage OA has not
been investigated. Additionally, if there were any effects,
would they be associated with changes in the ratio of OPG
to RANKL, MMP-9 and TLR-4 in cartilage and/or sub-
chondral bone?
Based on this hypothesis, we established a lapine model
of OA induced by anterior cruciate ligament transection
(ACLT) to investigate whether PAM could prevent or
even reverse subchondral bone loss and cartilage degener-
ation at the early stage of OA. Moreover, subchondral and
cartilaginous OPG, RANKL and relevant metabolic modu-
lators involved in cartilage and subchondral bone remod-
eling were also investigated.
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of Xu Zhou Medical University. The
protocol was approved by the Committee on the Ethics
of Animal Experiments of Xu Zhou Medical University
(Permit Number: SYXK (su) 2007-0037. All surgery was
performed under sodium pentobarbital anesthesia, and
all efforts were made to minimize pain and suffering.
Animals and study design
60 New Zealand white rabbits (8 months old) weighing ap-
proximately 2.5 kg were housed singly in cages in sanitary
ventilated animal rooms with controlled temperature and
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each rabbit was anesthetized by injection of 3% sodium
pentobarbital (30 mg/kg) into the ear vein. Each rabbit
was positioned supinely on the operation table. After sterile
draping, an incision was made in the side of the patella,
and additional local anesthesia with lidocaine intramuscu-
lar injection for the incision was given, followed by expo-
sure of the articular cavity. Intraoperative protections of
cartilage were noted. The right knee joint was shaved and
disinfected with isodine. ACLT was performed as described
by Yoshioka et al. [23]. A medial parapatellar incision was
made. After the patella was dislocated laterally, the knee
was flexed maximally so that the anterior cruciate ligament
could be readily visualized and identified. It was then trans-
ected with a No. 12 blade. An anterior drawing test was
performed gently to confirm that the ACL was transected
completely. The joint was irrigated with sterile saline and
closed. The joint capsule was closed with a running suture
of 4–0 nylon thread and the skin incision was closed with
running mattress sutures of 3–0 nylon thread. Sham opera-
tions were performed in a similar manner, except that
anterior cruciate ligament was not transected. After the op-
eration, muscular injection of Bucinnazine (25 mg/d) was
administered for postoperative analgesia. Free activity was
allowed in the cages without immobilization.
The rabbits were randomly divided into four groups as
follows. Sham-operated with vehicle treatment (Sham
group, n = 20), OA induced by ACLT with vehicle treat-
ment (ACLT group, n = 20), OA-induced ACLT treated
with short-term PAM (Sigma, Saint-Quentin Fallavier,
France) treatment after ACLT (PAM-S, n = 10), and
ACLT treated with long-term PAM treatment (PAM-L,
n = 10). PAM was injected at the 4th week after ACLT
in PAM-S and PAM-L groups, and followed by once
monthly ear vein injections at a dosage of 3 mg/kg body
weight. This dosage was chosen because it can fully im-
prove bone mineral density, osteogenic ability and mech-
anical properties [24]. In the other groups, only saline
infusions of equal volumes were administered. 10 animals
were humanely sacrificed at both 2 and 10 weeks after
PAM treatment. In the ACLT and Sham groups, five ani-
mals were sacrificed at 2, 4, 6, and 14 weeks after model
establishment. The experimental scheme is shown in
Figure 1a.
Micro-computerized tomography (micro-CT)
The proximal tibia of each rabbit was scanned and ana-
lyzed using the SkyScan1176 Micro-CT system and soft-
ware (version 1.1; Kontich, Belgium) with the following
specifications: voxel size 35 μm, voltage 65 kV, exposure
time 250 ms, frame averaging 1, beam filtration filter
1.0 mm aluminum. After scanning, the proximal tibia was
three-dimensionally reconstructed using SkyScan software
(version 1.1; Kontich). For analysis of the subchondralplate, the load-bearing region (1.04 × 1.04 cm2) was se-
lected as the region of interest (ROI). For analysis of sub-
chondral trabecular bone, a cuboid of trabecular bone
(1.04 × 1.04 × 1.52 cm3) beneath the ROI of the subchon-
dral plate was selected. Bone volume fraction (BV/TV, %),
trabecular thickness (TbTh, mm), trabecular number (TbN,
1/mm), trabecular separation (TbSp, mm), trabecular bone
pattern factor (TbPf, 1/mm), structure model index (SMI)
and degree of anisotropy (DA) were calculated for sub-
chondral trabecular bone.
Histology and OARSI score
Rabbits were euthanized [25] and the medial condyles
of the femurs were fixed with 4% paraformaldehyde
(Boster, Wuhan, China) overnight at 4°C on a shaker.
Whole medial condyles were decalcified in 14% ethylene-
diaminetetraacetic acid for 5 days at 4°C on a shaker. After
dehydration by gradient alcohol and infiltration by xylene
and paraffin, cartilage samples were embedded in paraffin.
Paraffin-embedded joints (4 μm) were sectioned on a sagit-
tal plane. Samples were stained with safranin O (Hengyuan,
Shanghai, China) and fast green (Hengyuan) using standard
protocols. All sections were evaluated for histologic signs of
cartilage degeneration using a modified Osteoarthritis Re-
search Society International (OARSI) scoring system [26].
Immunohistochemical localization of OPG and RANKL
Paraffin-embedded femur sections (4 μm) were prepared
to detect the distribution pattern of cartilaginous and
subchondral OPG and RANKL. The sections were incu-
bated with antibodies against OPG and RANKL (Santa
Cruz Biotechnology, Dallas, TX, USA). Briefly, tissue sec-
tions were washed twice with PBS containing 0.3% Tween
20 for 1 h and incubated with anti-OPG and anti-RANKL
polyclonal antibodies, followed by horseradish peroxidase-
labeled secondary antibody (Dako, Carpinteria, CA, USA).
The color (brown) was developed using 0.5 mg/ml 3,3′-
diaminobenzidine tetrahydrochloride. On negative control
slides, non-immune goat serum was substituted for the
primary antibody. On positive control slides, the brown-
yellow precipitate was developed as the OPG and RANKL
final product (see Additional file 1).
Western blot analysis
Separation of subchondral bone and cartilage
Proximal tibias were frozen in liquid nitrogen then placed
in an insulated box filled with liquid nitrogen to avoid pro-
tein degradation. Each proximal tibia was then stabilized
with a holding clamp. The articular cartilage and epiphys-
eal plate tissue of each femur condyle sample was cleared
away with a microelectronic burnishing instrument (Strong
80, 1 cw power, China) and a drill (SDE-H37L1, Marathon
Polishing Hand Grinder, Korea) to isolate the bone and
cartilage. During this process, we froze the samples using
Figure 1 Experimental design to study the effect of PAM on subchondral bone loss in ACLT- induced osteoarthritis. (a) Experimental
scheme. (b) Typical Micro-CT images selected of a highly representative subchondral bone sample for each group. (A,B) Sham-operated group,
(C) short-term treatment with PAM, (D) long-term treatment with PAM, (E-H) ACLT-induced osteoarthritis at 2, 4, 6 and 14 weeks. Marked differences in
the microarchitecture of subchondral bone were observed.
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tical Equipment Manufacturing Co, Shanghai, China) was
used to ensure that the articular cartilage and subchondral
bone were isolated.
Tissues from cartilage and subchondral bone were ho-
mogenized in liquid nitrogen, and protein extracted from
the resulting powder using a protein extraction buffer
containing 15 mM HEPES, 10% glycerol, 0.5% NP-40,
250 mM NaCl, 1 mM ethylene-diaminetetraacetic acid,
1:1000 PMSF, and a protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA). Protein determination
was carried out as described previously [27], and subse-
quently, 30 μg of protein from the cartilage and the
subchondral bone, respectively, were resolved on 15%
polyacrylamide sodium dodecyl sulfate gels. After trans-
fer to polyvinylidene difluoride membranes (Millipore,
Molsheim, France) in 48 mM Tris, 39 mM glycine and
20% methanol at 20 V for 1 h at room temperature,
membranes were blocked in 5% skimmed milk in PBS-Tween 20 for 1 h at room temperature and incubated over-
night at 4°C with anti-RANKL antibodies (sc-7628, 1:1000,
Santa Cruz), anti-OPG antibodies (sc-8468, 1:1000, Santa
Cruz), anti-MMP9 antibodies (BS-1241, 1:1000, Bioworld
Technology, St. Louis Park, MN, USA) and anti-TLR4
antibodies (ab183459, 1:800, Abcam, Cambridge, UK).
Antibody binding was detected by enhanced chemilumi-
nescence using peroxidase-labelled secondary antibodies
and the results are expressed as arbitrary densitometric
units. Loading control was performed on the 15% poly-
acrylamide-SDS gels using EZBlue Gel Staining Reagent
(Sigma-Aldrich).
Statistical analysis
All data are expressed as the means ± SEM. Statistical ana-
lyses were performed using the SPSS statistics package
(version 13.0, SPSS Inc., Chicago, IL, USA). The signifi-
cance of statistical data was analyzed using a two-way ana-
lysis of variance (ANOVA) to determine the “time effect”
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nificant, a paired t-test was applied and the P values were
adjusted for repeated comparisons using Holm’s Bonferroni
step-down procedure. A comparison between groups at
each time point was performed using a one-way ANOVA
with Tukey’s post hoc test. A value of P <0.05 was consid-
ered statistically significant.
Results
Establishment of ACLT-induced osteoarthritis model in
rabbits
All operations were performed smoothly without compli-
cations. At euthanasia, no significant variation in the body
weights between the experimental groups was observed
and the complete transection of each anterior cruciate
ligament was confirmed grossly. Periarticular areas were
generally clear or slightly blood tinged, with no gross signs
of inflammation or infection.
Impact of PAM on the structure of subchondral bone
Alterations in three-dimensional microstructures of the
subchondral bone are presented in Figure 1b. At 2 weeks
after model establishment, the ACLT group showed lower
BV/TV percentages, but higher TbSp, compared with the
Sham group (P <0.05, Figure 2). At 4 weeks after model
establishment, BV/TV and TbTh were both significantly
lower (P <0.05, Figure 2), but TbPf, SMI, TbSp and DA
were all significantly increased compared with the Sham
group (P <0.05, Figure 2). TbN consistently decreased
over the first 6 weeks after model establishment (P <0.05,
Figure 2), and these parameters changed continuously in
the same direction throughout the study period. After
2 weeks of treatment, the PAM group showed significantly
increased BV/TV, TbN and TbTh compared with the
ACLT group (P <0.05 or P <0.01); however, TbPf, TbSp,
DA and SMI were all significantly lower (P <0.05 or
P <0.01, Figure 2). After 10 weeks of PAM treatment, with
the exception of the slightly lower BV/TV percentage
(P <0.05), other parameters changed insignificantly com-
pared with the Sham group (Figure 2). The data indicate
that at 2 weeks after the establishment of ACLT-induced
OA in rabbits, changes in microstructures of the subchon-
dral bone had started to appear. At 4 weeks after model
establishment, related parameters in the subchondral bone
were altered significantly via treatment with PAM, indica-
ting that structures of the subchondral bone at the early
stage of OA had significantly improved.
Impact of PAM on the OARSI scores in the lapine
ACLT-induced model OA
Safranin O and fast green staining of cartilage tissue de-
tected no erosion-like changes in the cartilage surface at
any time in the Sham group (Figure 3a). In the ACLT
group, no significant changes were observed either inthe cartilage surface at 2 weeks after model establish-
ment (Figure 3d). However, at 4 weeks after model es-
tablishment, staining of safranin O had been partially
lost, indicating proteoglycan loss in the articular cartil-
age (Figure 3e). Various degrees of surface fibrosis,
cracks, cell loss and proliferation were observed in the
surface layer of the hyaline cartilage. In the ACLT group
at 6 and 14 weeks after model establishment, the follow-
ing observations were recorded: chondrocytes of the
hyaline cartilage surface were markedly reduced, fibrosis
was extensive, osteophytes had formed, vertical fractures
had increased and safranin O staining in the cartilagin-
ous area was significantly reduced (Figure 3f and g).
Compared with the ACLT group, at 2 and 10 weeks after
PAM treatment, chondrocytes and matrices in the PAM
group were significantly increased, fibroses of the cartil-
age surface were significantly reduced, and no increase
in fractures was observed (Figure 3b and c). Moreover,
OARSI scores indicated that PAM prevented and attenu-
ated an increase in OA (P <0.05 or P <0.01, Figure 4).
These results indicate that PAM treatment in the PAM-
S and PAM-L groups both prevented OA alterations in
chondrocyte morphology and losses in the cartilaginous
matrix, or that PAM treatment may have reversed the
pathological lesions of the articular cartilage (Figure 3).
Correlations between cartilage and bone changes
Associations between OARSI scores and the micro-CT
bone structure assessments at 6 weeks and 14 weeks are
illustrated in Figures 5 and 6. Significantly negative corre-
lations were identified between OARSI scores and BV/TV
percentage (P <0.05), TbTh (P <0.05), and TbN (P <0.01),
but significantly positive correlations were identified for
TbSp (P <0.05), TbPf (P <0.01), SMI (P <0.05), and DA
(P <0.01). Importantly, the subchondral bone changes cor-
related with the cartilage lesions, providing additional evi-
dence that subchondral bone is involved and plays a
critical role in the pathogenesis of ACLT-induced OA.
Impact of PAM on OPG and RANKL expression in
subchondral bone and cartilage
Western blot indicated that protein expression of OPG
and RANKL was present in cartilage and subchondral
bone tissue in all groups (Figure 7). Compared with the
Sham group, protein expression of OPG and RANKL in
cartilage and subchondral bone tissues in the ACLT group
were both significantly higher (P <0.05 and P <0.01), al-
though the increase in RANKL expression was more sig-
nificant than that of OPG (Figure 7). Therefore, the ratios
of OPG/RANKL in cartilage and subchondral bone in the
ACLT group were lower than in the Sham group (P <0.01,
Figure 7e and f). However, protein expression of OPG in
the articular cartilage and subchondral bone in both PAM
groups were significantly higher when compared with
Figure 2 Quantitative analyses of the subchondral bone morphometric parameters from Micro-CT. Bone parameters assessed included
(a) BV/TV, (b) DA, (c) SMI, (d) TbPf, (e) TbSp, (f) TbTh, (g) TbN. * and ** indicate groups significantly different from the sham-operated rabbits
treated with vehicle (*P <0.05 and ** P <0.01). # and ## indicate significant differences between the ACLT group and rabbits treated with pamidronate.
(# P <0.05 and ##: P <0.01).
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Figure 7a and b). Compared with the ACLT group, ex-
pression of RANKL in both PAM groups was lower
(Figure 7c and d). Hence, the OPG/RANKL ratios in
the PAM group were significantly higher, compared ei-
ther with those of the Sham or ACLT groups (P <0.01,
Figure 7e and f ).
Immunohistochemical analyses detected low expres-
sion of RANKL and OPG in cartilaginous chondrocytes
and subchondral bone osteoblasts in the Sham group
(Figure 8a, f, k and p). In the ACLT group, OPG-positive
cells were slightly more numerous (Figure 8g, h, q and r),and RANKL-positive cells were significantly more numer-
ous (Figure 8b, c, l and m), respectively. Compared with
the ACLT group, OPG-positive cells were significantly
more numerous in both articular cartilage and subchon-
dral bone in both PAM groups (Figure 8i, j, s and t). Fur-
thermore, the numbers of RANKL-positive cells in both
articular cartilage and subchondral bone were also signifi-
cantly lower (Figure 8d, e, n and o). These results indicate
that PAM significantly increased the OPG/RANKL ratio
in this lapine model of ACLT-induced OA. Therefore,
these immunohistochemical results also confirm the west-
ern blot and micro-CT results.
Figure 3 Effects of PAM treatment on cartilage surface erosion. The sections were stained with safranin-O (red stain) for glycosaminoglycans,
rapid green for bone. (a) The Sham group had no erosion-like changes in the cartilage surface. (b,c) Short-term and long-term treatment with
PAM significantly increased chondrocytes and matrices, while fibroses of the cartilage surface were significantly reduced compared with the ACLT
group at 6 and 14 weeks. (d) ACLT group at 2 weeks, no significant changes were observed in the cartilage surface. (e) ACLT group at 4 weeks,
staining of safranin O had been partially lost and various degrees of surface fibrosis, cracks, cell loss proliferation were observed in the surface
layer of the hyaline cartilage. (f,g) ACLT group at 6 and 14 weeks, chondrocytes of the hyaline cartilage surface were massively reduced, fibroses
were extensive, osteophytes had formed, vertical fractures had increased and safranin O staining in the cartilaginous area was significantly reduced. Bar
represents 200 μm.
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subchondral bone and cartilage
Western blot results showed low expression of MMP-9
and TLR4 in the Sham group (Figure 9). In contrast to the
Sham group, expression of MMP-9 and TLR4 was signifi-
cantly higher in the ACLT group (P <0.01, Figure 9).Figure 4 Assessment of articular cartilage changes according to
the 2010 OARSI recommendations in the rabbit. The score
represents the sum of the scores of staining, structure, chondrocyte
density and cluster formation. A significant increase of OARSI scores
in the ACLT group can be observed with time, and PAM can prevent
and lower the increase in the OA scores, compared with the ACLT
group at 4 weeks. *P <0.05, **P <0.01, # indicates group significantly
different from the sham-operated rabbits treated with vehicle (# P <0.05
and ## P <0.01).Notably, compared with the ACLT group, expression of
MMP-9 and TLR4 in the PAM treated groups was signifi-
cantly down-regulated (P <0.01). These data indicate that
timely treatment with PAM can counteract subchondral
bone degradation as determined by MMP-9 protein ex-
pression and can reduce the cartilage destruction and in-
flammation associated with TLR4 activation. Therefore,
these western blot results are also in accord with the hist-
ology and micro-CT results.Discussion
OA is mainly characterized by wearing of the articular
cartilage and abnormal remodeling in the subchondral
bone [1]. To date, its pathogenesis remains unknown
and there is no known cure. Some studies indicate that
increased subchondral bone remodeling could lead to car-
tilage degeneration initially [1,28]. Mechanically, the sub-
chondral bone supports the overlying cartilage and
absorbs the forces transmitted by the joint. Mineralization
of the subchondral bone and increased rigidity reduce its
buffering and load balancing capacities and thus accelerate
the cartilage degeneration process [3,29]. However, some
scholars have posited that changes in subchondral bone
could exist during or after cartilaginous degeneration [10].
Therefore, whether the development of OA originates
Figure 5 Correlations between the OARSI score and the micro-CT quantitative bone parameters at 6 weeks. (a) BV/TV, (b) DA, (c) SMI,
(d) TbPf, (e) TbSp, (f) TbTh, (g) TbN. Significant negative correlations were identified between OARSI scores and BV/TV, TbTh and TbN, and
significant positive correlations were identified between OARSI scores and TbSp, TbPf, SMI and DA at 6 weeks. P values are indicated on a where
statistically significant. The symbols represent the different specimens (● = Sham group,▲ = PAM-S group, □ = ACLT group)
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controversial.
In the present study, at 2 weeks after model establish-
ment, the BV/TV of the subchondral bone was signifi-
cantly reduced and the TbSp was increased, indicating
that bone loss had begun in this ACLT-induced OA
model. However, at 2 weeks after model establishment,
the OARSI score of the articular cartilage in the ACLT
group was not significantly different from that of the
Sham group (P >0.05, Figure 4). Therefore, subchondral
bone changes preceded the changes in the articular car-
tilage in this OA model.
To explore the methods of treatment to protect
against articular cartilage deterioration and subchondral
bone loss, bone anticatabolic agents such as bisphospho-
nates may be used as a means to inhibit the subchondral
bone resorption [1-4]. Although limited clinical researches
have shown beneficial effects of bisphosphonates on sub-
chondral bone and prevent the progression of OA, thereFigure 6 Correlations between the OARSI score and the Micro-CT qua
(d) TbPf, (e) TbSp, (f) TbTh, (g) TbN. Significant negative correlations were
significant positive correlations were identified between OARSI scores and Tb
statistically significant. The symbols represent the different specimens (● = Shis no study evaluating a selected sample of patients with
early OA owing to ethical reasons. In a 2-year trial, risedro-
nate, also a member of bisphosphonate family, decreased
biochemical markers of cartilage degeneration and partial
symptoms, but did not prevent the radiographic progres-
sion of advanced OA [30]. Furthermore, the majority of
bisphosphonates treatment animal programs have been
initiated several days before or on the day of OA animal
model establishment [1,3,20-22]. The aforementioned
studies suggest that further studies are necessary to evaluate
the importance of timing of treatment with anti-resorptive
agents in the early stage of OA.
In this study, treatment with PAM was initiated at
4 weeks after OA establishment. Compared with the ACLT
group, BV/TV, TbN and TbTh were all significantly higher,
while TbPf, TbSp, Da and SMI were all significantly lower
in the PAM treated groups (Figure 2). After 2 weeks of
PAM treatment, loss of subchondral bone was significantly
reduced and osteogenic ability was significantly improved.ntitative bone parameters at 14 weeks. (a) BV/TV, (b) DA, (c) SMI,
identified between OARSI scores and BV/TV, TbTh and TbN, and
Sp, TbPf, SMI and DA at 14 weeks. P values are indicated on b where
am group,▲ = PAM-L group, □ = ACLT group).
Figure 7 Effects of PAM treatment on OPG and RANKL protein expression and OPG/RANKL ratio in cartilage and subchondral bone.
Relative levels measured by western-blotting are shown, (a) OPG protein expression in cartilage, (b) OPG protein expression in subchondral bone,
(c) RANKL protein expression in cartilage, (d) RANKL protein expression in subchondral bone, (e) Ratio of OPG/RANKL in cartilage, (f) Ratio of
OPG/RANKL in subchondral bone. * and ** indicate groups significantly different from the sham-operated rabbits treated with vehicle (*P <0.05
and **P <0.01). # and ## indicate significant differences between the ACLT group and rabbits treated with pamidronate. (# P <0.05 and ## P <0.01).
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http://www.biomedcentral.com/1471-2474/15/370After 10 weeks of PAM treatment, only BV/TV was re-
duced (P <0.05) compared with the Sham group (Figure 2).
These results indicate that PAM treatment stopped bone
loss in the subchondral bone and even reversed the patho-
logical lesions in the subchondral bone after long-term
therapy.
We used the ACL transection rabbit model for the study
of cartilage lesions, as it reproduces all of the OA-associated
lesions in arthrosis. Moreover, the ACLT model is a sig-
nificant risk factor for development of post-traumatic
osteoarthritis, which loses the proteoglycan and collagen
molecules from cartilage in the first few weeks after anter-
ior cruciate ligament injury [31]. The response of cartilage
lesions to therapy can be graded according to an adapted
histological and histochemical grading system (OARSI
score) that is evaluated via staining for structure, chondro-
cyte density and cluster formation [26,32]. In this study, at
4 weeks after model establishment, safranin O staining inthe ACLT group was partially lost and fibroses were ob-
served on the surface of hyaline cartilage (Figure 3),
indicating loss of articular cartilage proteoglycan and
induction of early OA. Thereafter, OA-like signs of
massive reduction of chondrocytes, loss of matrices, ex-
tensive fibroses, and formations of osteophyte and ver-
tical cracks appeared at 6 and 14 weeks (Figure 3f and g)
[33]. However, both PAM groups stopped or improved
the morphological changes in chondrocytes and loss of
cartilage matrix in early-stage OA and OARSI scores in
the PAM group were significantly lower than those of
the ACLT group (P <0.01, Figure 4). More importantly,
both short- and long-term treatments attenuated the
articular lesions generated (Figures 3, 4). Moreover, excel-
lent correlations were established between parameters of
microstructure in subchondral bone and the cartilage
damage score. Significant negative correlations were iden-
tified between OARSI scores and BV/TV, TbTh and TbN,
Figure 8 Effects of PAM treatment on expression of RANKL and OPG in the cartilage and subchondral bone. (a–e) Immunohistochemical
detection of RANKL expression in cartilage in Sham (a), ACLT (b,c) and PAM (d,e) samples, arrows point to positive cells. (f–j) OPG positive cells
in the cartilage of the indicated samples. (k–o) RANKL positive cells in the subchondral bone samples. (p–t) OPG positive cells in the subchondral
bone samples. Bar represents 100 μm.
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http://www.biomedcentral.com/1471-2474/15/370and significant positive correlations were identified between
OARSI scores and TbSp, TbPf, SMI and DA (Figures 5 and
6). Thus, these data provide further support that subchon-
dral bone loss and cartilage lesions are closely related.
Specifically, the improvement of microstructure and sub-
chondral bone remodeling following treatment with PAM
would markedly contribute to the avoidance of progression
of cartilage damage in our experimental model.Figure 9 Effect of PAM treatment on MMP9 and TLR4 protein express
measured by western blot are shown, (a) MMP9 protein expression in cartilage
** indicate groups significantly different from the sham-operated rabbits treate
differences between the ACLT group and rabbits treated with pamidronate. (#To elucidate the mechanisms by which PAM protects
against articular cartilage and subchondral bone erosion
in OA, we investigated the RANKL/OPG system in both
subchondral bone and cartilage. It is reported that in a
rat knee model of osteoporosis, alendronate treatment at
the early or late stages could both raise the ratio of OPG
to RANKL [3]. However, Reyes-Garcia et al. measured
serum levels of OPG and RANKL in women receivingion in cartilage and subchondral bone. Relative protein levels as
and (b) subchondral bone. (c) TLR4 protein expression in cartilage. * and
d with vehicle (*P <0.05 and **P <0.01). # and ## indicate significant
P <0.05 and ## P <0.01).
Lv et al. BMC Musculoskeletal Disorders 2014, 15:370 Page 11 of 12
http://www.biomedcentral.com/1471-2474/15/370alendronate treatment for postmenopausal osteoporosis
and found that total serum RANKL levels increased dur-
ing the one-year treatment [34]. Moreover, a recent study
has demonstrated that OPG could reduce aggrecan cleav-
age and cartilage proteoglycan release and then represent
the protective role in the regulation of cartilage catabolism
[1]. In this study, western blot and immunohistochemistry
analysis indicated that the ratio of OPG to RANKL in
both cartilage and subchondral bone was significantly in-
creased after short- and long-term treatments with PAM
in ACLT-induced OA (Figures 7 and 8). Obviously, the re-
sults suggest that PAM treatment could upregulate OPG
expression, while downregulating RANKL expression in
both subchondral bone and cartilage.
Since the central clinicopathological features of the pro-
gression of OA are inflammation and articular cartilage
destruction, MMP-9 was considered an important pro-
teinase to investigate as it can degrade all components of
the complex extracellular matrix in terms of cartilage deg-
radation [16]. Furthermore, many studies have shown that
upregulation of MMP-9 results in destruction of articular
cartilage in OA patients [35,36]. TLRs are an important
type of pathogen receptor of the innate immune system
that have drawn much attention in the study of OA in re-
cent years [37,38]. Some studies have shown that TLR4 is
involved in AGE-induced chondrocyte inflammation in
OA in humans [15]. Moreover, one study showed that
TLR-4 was capable of regulating the early onset of joint
inflammation and cartilage destruction in a murine model
of immune complex-mediated arthritis and was closely as-
sociated with cartilage destruction [37]. Thus, we detected
the expression of MMP-9 and TLR-4 by western blot.
Interestingly, we found that the expression of MMP-9 and
TLR4 in the ACLT group was significantly higher com-
pared with the Sham group. However, expression of MM
P-9 and TLR4 in both PAM treated groups was downregu-
lated compared with the ACLT group (P <0.01, Figure 9).
Thus, we considered the results to at least provide an add-
itional explanation regarding the control of joint inflamma-
tion and mild degeneration in the knee joint of the rabbit
after PAM treatment.
Conclusions
We successfully established an ACLT-induced OA animal
model in rabbits. First, we verified the important roles of
subchondral bone loss in the pathogenesis of OA and its
early incidence before cartilaginous degeneration. Mean-
while, we also found that intervention with PAM at 4 weeks
after ACLT-induced OA establishment inhibited subchon-
dral bone loss. Continuous treatment may have reversed
the pathological changes in subchondral bone, thus allevi-
ating the process of cartilaginous degeneration. This pro-
tection occurred via the upregulation of OPG expression
and inhibition of RANKL and MMP-9 expression in thecartilage and subchondral bone, and TLR-4 expression in
the cartilage.
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